Phase 3 trial of oral ALZ-801 in Early AD patients who are homozygous for the epsilon 4 variant of the Apolipoprotein E gene (APOE4/4)

Brief description of study

The purpose of this study is to determine if the study drug called ALZ-801 is safe, if it is well tolerated (how your body reacts to the study drug) and if it is effective in treating Alzheimer’s Disease (AD). ALZ-801 has an active agent called tramiprosate, which interferes with the formation of abnormal forms of a protein called beta amyloid or Aß-42. These abnormal amyloid proteins are thought to play an important role in causing cell damage in the brain and the development of AD. ALZ-801 inhibits the formation of these abnormal toxic proteins and may be able to slow down or stop the worsening of AD. To determine if ALZ-801 is effective, a comparison must be made between ALZ-801 and placebo. A placebo looks like the study drug but does not contain any active drug. Researchers use a placebo to see if a study drug works better or is safer than not taking anything at all.


Clinical Study Identifier: s20-01820
ClinicalTrials.gov Identifier: NCT04770220
Principal Investigator: Thomas M Wisniewski.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.